Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat Immune Thrombocytopenia

Thrombocytopenia News

Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat Immune Thrombocytopenia
Platelet CountThrombocyte CountPlatelets
  • 📰 Medscape
  • ⏱ Reading Time:
  • 43 sec. here
  • 22 min. at publisher
  • 📊 Quality Score:
  • News: 90%
  • Publisher: 55%

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in patients with previously treated immune thrombocytopenia.

Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase inhibitor for patients with previously treated

Briefing moderator Charles Abrams, MD, University of Pennsylvania, Philadelphia, noted that LUNA 3 enrolled a"remarkably tough group of patients, really the hardest of the hard" and showed that rilzabrutinib was"well-tolerated and caused an increase in platelet counts." "People living with immune thrombocytopenia who cannot tolerate or do not respond to medications aimed at raising platelet counts are at risk of uncontrolled bleeding and often endure side effects from steroids and other available therapies," Kuter noted in a Sanofi

Platelet response — defined as counts at or above 50,000/μL or counts between 30,000/μL and 50,000/μL but doubled from baseline — was achieved in nearly two thirds of patients taking rilzabrutinib compared with almost one third of patients taking placebo at week 13.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Platelet Count Thrombocyte Count Platelets Thrombocytes Platelet Count (PLT) Thromboembolism Immune Thrombocytopenia Fatigue Quality Of Life QOL Health Related Quality Of Life Health-Related Quality Of Life HRQOL Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenic Purpura Pain Management Hematology Haematology Patient Safety Thrombocytopenic Purpura

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

First TAVR for Aortic Regurgitation Moves to Phase 3 TrialFirst TAVR for Aortic Regurgitation Moves to Phase 3 TrialThe first transcatheter aortic valve replacement device designed specifically to control aortic regurgitation performs well at 2 years in advance of randomized trial, reported investigators.
Read more »

FDA Considers New Dupilumab Data for Chronic Spontaneous Urticaria IndicationFDA Considers New Dupilumab Data for Chronic Spontaneous Urticaria IndicationAdditional phase 3 trial results confirmed improvement in hives and itching.
Read more »

Mike Madigan trial live updates: Jury seated to hear more testimony in former IL speaker trialMike Madigan trial live updates: Jury seated to hear more testimony in former IL speaker trialTrial expected to last months
Read more »

Mike Madigan trial live updates: Ed Moody takes stand in ex-Illinois speaker trialMike Madigan trial live updates: Ed Moody takes stand in ex-Illinois speaker trialTrial expected to last months
Read more »

Mike Madigan trial live updates: Former Ald. Michele Smith takes stand in ex-Illinois speaker trialMike Madigan trial live updates: Former Ald. Michele Smith takes stand in ex-Illinois speaker trialTrial expected to last months
Read more »

Daniel Penny’s trial draws parallels with 40-year-old trial that took country by stormDaniel Penny’s trial draws parallels with 40-year-old trial that took country by stormPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »



Render Time: 2025-02-16 04:56:59